Ca channel blocker and heart failure

Shintaro Kinugawa, Hiroyuki Tsutsui

研究成果: ジャーナルへの寄稿総説査読

1 被引用数 (Scopus)


Ca channel blocker (CCB) inhibits the entry of calcium ion through L-type calcium channel in the vascular smooth muscle, and possesses the blood pressure lowering action. It was expected that CCB might be useful for the treatment of heart failure (HF) because of its vasodilating action. However, the prospective, randomized, double-blind, crossover studies have shown that the short-acting CCBs rather increase morbidity and mortality in patients with chronic HF during the long-term follow-up. It would be due to the fact that CCBs increase the sympathetic nerve activity and cause tachycardia in response to their acute vasodilating effects. Amlodipine, the long-acting CCB, has been shown to have a neutral effect on morbidity and mortality in patients with HF. Recently, new CCBs, which do not increase heart rate, have been developed. These drugs exert the inhibitory action for N- or T-type Ca channel or directly prevent sympathetic nerve activity. Furthermore, some CCBs may act protectively in HF by stimulating nitric oxide production and/or inhibiting oxidative stress. Newly developed CCBs promise to be useful for the treatment of chronic HF.

ジャーナルClinical calcium
出版ステータス出版済み - 10月 2005

!!!All Science Journal Classification (ASJC) codes

  • 医学一般


「Ca channel blocker and heart failure」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。